Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative ...
During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...
A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome ...
News-Medical.Net on MSN4d
Tirzepatide helps people without diabetes lose 13% body weight in real-world studyA real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...
News Medical on MSN1d
FXR cyclic peptide antagonists as a novel strategy for MASH treatmentIn this study, the authors first used an AlphaScreen assay to identify a series of tryptophan-based cyclic peptide compounds with FXR-antagonistic activity, specifically those modified with a ...
G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...
Zacks Investment Research on MSN4d
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
The following is a summary of “Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a ...
For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...
Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback